

Barcelona, June 30<sup>th</sup>, 2026

## **OTHER RELEVANT INFORMATION**

### **Almirall divests its Actithiol franchise**

In accordance with Securities Markets Law, Almirall S.A. (“Almirall”) announces the following:

Almirall divests its Actithiol franchise. This is part of the regular business management and optimization of the existing portfolio and is incorporated in our 2026 guidance.

This is a divestment of our Actithiol franchise, which comprises mucolytic products indicated for the relief of symptoms associated with excess mucus, cough and nasal congestion. The divestment includes three assets: Actithiol Antihistamine, Actithiol Pediatric, and Mucoactiol.

The transaction value is €15 million, with €13 million paid upfront plus €2 million subject to the achievement of certain milestones.

Sincerely,

Pablo Divasson del Fraile  
Investor Relations Department  
[investors@almirall.com](mailto:investors@almirall.com)